[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Li HC, Patel P, Kapur P, Huerta S: Metastatic rectal cancer to the breast. Rare Tumors; 2009;1(1):e22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic rectal cancer to the breast.
  • Rectal cancer metastatic to the breast is an exceedingly rare event with around 15 cases reported in the literature.
  • A metastatic breast deposit from the rectum signifies diffuse disseminated disease or a highly aggressive tumor such that surgical intervention other than palliation has a limited role.
  • In the present report, we discuss a patient who presented with rectal cancer and developed a breast metastatic deposit.
  • She soon developed progressive metastatic involvement of the lungs and the soft tissues and succumbed to the malignant course of this disease 12 months after the diagnosis of the primary rectal tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139894.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994444
  • [Keywords] NOTNLM ; colonoscopy. / fine needle aspiration / metastatectomy / palliative surgery
  •  go-up   go-down


2. Casaccia M, Famiglietti F, Andorno E, Di Domenico S, Ferrari C, Valente U: Simultaneous laparoscopic anterior resection and left hepatic lobectomy for stage IV rectal cancer. JSLS; 2010 Jul-Sep;14(3):414-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous laparoscopic anterior resection and left hepatic lobectomy for stage IV rectal cancer.
  • We report the case of a 68-year-old female patient affected by rectal cancer and a synchronous metastatic lesion measuring 8 cm in diameter in the left hepatic lobe.
  • After a laparoscopic ultrasonography exploration of the liver to detect possible occult metastases, a simultaneous colorectal resection and a left hepatic lobectomy including a partial resection of segment IV were performed.
  • This report confirms the feasibility of the laparoscopic approach to simultaneous hepatic and colorectal resections in stage IV rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2006 Jan;93(1):67-72 [16273531.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):254-9 [16858188.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Oct;16(5):486-8 [17004874.001]
  • [Cites] Surgery. 2007 Feb;141(2):203-211 [17263977.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1143-50 [17200913.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3481-91 [17805933.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1424-8 [18253800.001]
  • [Cites] Surgery. 2008 Sep;144(3):436-41 [18707042.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2701-6 [18843442.001]
  • [Cites] Colorectal Dis. 2009 Jan;11(1):3-10 [18637099.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):44-52 [19071061.001]
  • [Cites] Br J Surg. 2009 Mar;96(3):274-9 [19224518.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):158-9 [12399864.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • (PMID = 21333199.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3041042
  •  go-up   go-down


3. Kitai Y, Takahashi H, Goto A, Iida H, Mawatari H, Fujita K, Yoneda M, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A: Chemotherapeutic treatment of priapism in metastatic rectal cancer. Case Rep Gastroenterol; 2008 Sep;2(3):505-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic treatment of priapism in metastatic rectal cancer.
  • Enhanced computed tomography revealed metastatic tumors in the liver, lung, sacrum and lymph nodes.
  • Advanced rectal cancer, detected by colonoscopy as a primary tumor, was treated with chemotherapy (FOLFOX4).
  • Although the rectal cancer showed no change, five months of chemotherapy improveid the priapism, suggesting that chemotherapy can improve rare symptoms of rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hinyokika Kiyo. 2001 Sep;47(9):665-7 [11692608.001]
  • [Cites] Am Surg. 2001 May;67(5):454-7 [11379648.001]
  • [Cites] Am J Health Syst Pharm. 2008 Jun 1;65(11 Suppl 4):S15-21; quiz S22-4 [18499885.001]
  • [Cites] Clin Transl Oncol. 2007 Nov;9(11):742-3 [18055330.001]
  • [Cites] Turk Neurosurg. 2007 Oct;17(4):260-3 [18050069.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2002 May;93(4):568-72 [12056042.001]
  • [Cites] Ann Intern Med. 1972 May;76(5):793-9 [4623586.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:48-53 [17124039.001]
  • [Cites] Int J Urol. 2004 Sep;11(9):809-10 [15379953.001]
  • [Cites] Ann Urol (Paris). 2003 Jun;37(3):143-5 [12872608.001]
  • [Cites] Surg Today. 2005;35(8):692-5 [16034553.001]
  • (PMID = 21897807.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3166819
  • [Keywords] NOTNLM ; Chemotherapy / Metastatic rectal cancer / Priapism
  •  go-up   go-down


Advertisement
4. Fekrazad MH, Eberhardt S, Jones DV, Lee FC: Development of bronchiolitis obliterans organizing pneumonia with platinum-based chemotherapy for metastatic rectal cancer. Clin Colorectal Cancer; 2010 Jul;9(3):177-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of bronchiolitis obliterans organizing pneumonia with platinum-based chemotherapy for metastatic rectal cancer.
  • Bronchiolitis obliterans organizing pneumonia (BOOP) is an adverse event known to occur after cancer chemotherapy and radiotherapy.
  • We present a case of a 47-year-old patient who was diagnosed with BOOP after treatment for metastatic rectal cancer with oxaliplatin/capecitabine/bevacizumab.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Rectal Neoplasms / drug therapy


5. Miyake Y, Kato T, Oshima S, Iijima S, Kurokawa E, Okamoto Y, Kumazawa K, Chin R, Amemiya K, Adachi K, Kikkawa N: [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2317-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary].
  • Under diagnosis of a primary rectal cancer with peritonitis, an ileostomy was scheduled.
  • Since peritoneal dissemination was found, histologically she was diagnosed as metastatic rectal cancer from serous adenocarcinoma of the ovary.
  • Eight months after the first operation, she underwent total hysterectomy, oophorectomy and low anterior resection of rectum.
  • No viable cancer tissue could be found.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Rectal Neoplasms / secondary

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Ghosh D, Boama V: Undiagnosed rectal tumour--a rare cause of obstructed labour in the second stage. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undiagnosed rectal tumour--a rare cause of obstructed labour in the second stage.
  • Colorectal cancer presenting in pregnancy is extremely rare.
  • Here the authors present the case of a 25-year-old woman who was diagnosed with second-stage obstructed labour secondary to a large rectal tumour.
  • Histology later confirmed villous adenocarcinoma of the rectum.
  • The patient died from metastatic rectal cancer within 2 years of diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cesarean Section. Dystocia / surgery. Pregnancy Complications, Neoplastic / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Constriction, Pathologic / etiology. Constriction, Pathologic / surgery. Delivery, Obstetric. Female. Follow-Up Studies. Gestational Age. Humans. Labor Stage, Second. Pregnancy. Pregnancy Outcome. Rare Diseases

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynaecol Obstet. 1987 Aug;25(4):337-40 [2887470.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1995 Nov;63(1):95-6 [8674574.001]
  • [Cites] Gastroenterol Clin North Am. 1998 Mar;27(1):225-56 [9546092.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1998 Nov;38(4):474 [9890239.001]
  • [Cites] J Reprod Med. 2007 Jun;52(6):545-7 [17694979.001]
  • [Cites] Arch Gynecol Obstet. 2009 Mar;279(3):427-9 [18665376.001]
  • [Cites] Br J Obstet Gynaecol. 1978 Mar;85(3):231-3 [629904.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Sep;86(9):747-8 [497148.001]
  • [Cites] Dis Colon Rectum. 1981 Sep;24(6):473-5 [7273986.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1985 Nov;20(5):325-8 [3908181.001]
  • (PMID = 22767473.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030301
  •  go-up   go-down


7. Loi S, Ngan SY, Hicks RJ, Mukesh B, Mitchell P, Michael M, Zalcberg J, Leong T, Lim-Joon D, Mackay J, Rischin D: Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer; 2005 Feb 28;92(4):655-61
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
  • Eligible patients had inoperable rectal cancer, or symptomatic primary rectal cancer with metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Misonidazole / analogs & derivatives. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1140-6 [15894548.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):111-8 [11134203.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2433-8 [11331322.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):397-402 [12243813.001]
  • [Cites] Ann Nucl Med. 2002 Sep;16(6):409-16 [12416580.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3098-104 [12915600.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Adv Exp Med Biol. 1984;180:293-300 [6534106.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] Adv Exp Med Biol. 1994;345:459-63 [8079744.001]
  • [Cites] World J Surg. 1996 Feb;20(2):245-7 [8661826.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1130-5 [9278661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • (PMID = 15700033.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 0 / Radiopharmaceuticals; 04ZR38536J / oxaliplatin; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 13551-89-8 / fluoromisonidazole; 8FE7LTN8XE / Misonidazole; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361867
  •  go-up   go-down


8. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE: A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer; 2010 Apr;9(2):119-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
  • BACKGROUND: Standard therapy for stage II/III rectal cancer consists of a fluoropyrimidine and radiation therapy followed by surgery.
  • Preclinical data demonstrated that bortezomib functions as a radiosensitizer in colorectal cancer models.
  • PATIENTS AND METHODS: Patients with locally advanced rectal adenocarcinomas, as staged by endoscopic ultrasound, were eligible.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 2001 Apr;155(4):543-53 [11260656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93 [11316563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):883-7 [11429215.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6316-25 [14695130.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2615-22 [10363983.001]
  • [Cites] Dis Esophagus. 2009;22(2):127-32 [19021681.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5620-7 [16009958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12 [16005577.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3930-5 [17761976.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4175-85 [18593997.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):537-40 [18783399.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • (PMID = 20378507.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / K23 CA118431; United States / NCRR NIH HHS / RR / KL2 RR025746-02; None / None / / KL2 RR025746-02; United States / NCI NIH HHS / CA / P50CA106991; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCRR NIH HHS / RR / UL1 RR024975; United States / NCI NIH HHS / CA / P50CA95103; United States / NCI NIH HHS / CA / P30CA068485; United States / NCI NIH HHS / CA / K23CA118431; United States / NCI NIH HHS / CA / P50 CA106991
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / NF-kappa B; 0 / Pyrazines; 69G8BD63PP / Bortezomib; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS200786; NLM/ PMC2893386
  •  go-up   go-down


9. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery. Rectum / surgery. Sigmoid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Shinozaki E, Mizunuma N, Tanabe M, Chin K, Ota K, Ohkochi N, Hatake K: [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer]. Gan To Kagaku Ryoho; 2005 Mar;32(3):397-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer].
  • We report a case on hemodialysis with metastatic rectal cancer who was introduced to CPT-11.
  • CPT-11 is not only the key compound for metastatic colorectal cancer, but is also effective with several other cancers.
  • It is important for cancer patients with chronic renal failure that the feasibility and efficacy of CPT-11 should be determined by future study.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Rectal Neoplasms / drug therapy. Renal Dialysis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791826.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • METHODS: Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008.
  • The outcomes for patients who underwent synchronous resection, staged resection, resection of rectal tumor only, and no resection with chemotherapy only were compared.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Tashima R, Yokoyama S, Yamashita Y, Baba K, Matsuda M: [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1663-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].
  • The FOLFIRI regimen (irinotecan in combination with bolus and continuous infusion of 5-FU and l-LV) and FOLFOX regimen (oxaliplatin/5-FU/LV therapy) are now standard chemotherapy for metastatic colorectal cancer in Western countries.
  • Here, we report a case of metastatic rectal cancer showing a complete response (CR) to cycle 4 in FOLFIRI regimen, while maintaining a CR status for over 11 months and good QOL, as a result of chemotherapy with 4 cycles of FOLFIRI followed by UFT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940386.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol; IFL protocol
  •  go-up   go-down


13. Oztop I, Yaren A, Demirpence M, Alacacioglu I, Tuna B, Piskin O, Yilmaz U: The development of metachronous prostate cancer and chronic myeloid leukemia in a patient with metastatic rectal cancer. J BUON; 2008 Apr-Jun;13(2):267-70
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of metachronous prostate cancer and chronic myeloid leukemia in a patient with metastatic rectal cancer.
  • We report herein an unusual case of metachronous triple cancers (rectum, prostate and Philadelphia(+) [Ph(+)] chronic myeloid leukemia [CML]).
  • A metastatic rectal cancer was diagnosed in a 76-year-old male patient, who was treated with transanal tumor resection and chemotherapy.
  • Thirty months from the initial rectal cancer diagnosis, prostate cancer was diagnosed and the patient was administered maximal androgen blockade and received palliative radiotherapy to the lumbar spine because of painful bone metastases.
  • Thirty months after the diagnosis of rectal cancer and 12 months after the diagnosis of prostate cancer the patient developed Ph(+) CML and imatinib treatment was started.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Rectal Neoplasms / pathology. Stomach Neoplasms / pathology


14. Nozawa H, Muto Y, Yamada Y: Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Clin Ther; 2008 Jun;30(6):1160-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
  • Oxaliplatin is a therapeutic platinum compound used for the treatment of colorectal cancer; however, it might induce hypersensitivity reactions, a critical situation that requires discontinuation of chemotherapies that contain oxaliplatin.
  • This letter reports a 53-year-old Japanese woman (weight, 70 kg) with chemorefractory metastatic rectal cancer who had undergone surgical intervention twice and received 3 treatment regimens.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Desensitization, Immunologic / methods. Drug Hypersensitivity / drug therapy. Organoplatinum Compounds / adverse effects. Premedication / methods. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640472.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


15. Huang GC, Chen LJ, Liu HC, Chen YJ: Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer. Clin Drug Investig; 2008;28(8):523-6
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer.
  • This case report describes a 68-year-old [corrected] male with rectal cancer who developed a vitreous haemorrhage during treatment with bevacizumab.
  • This implies that AMD might serve as a risk factor for vitreous haemorrhage in cancer patients treated with systemic bevacizumab.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Rectal Neoplasms / drug therapy. Vitreous Hemorrhage / chemically induced

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Drug Investig. 2008;28(11):739
  • (PMID = 18598098.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 6T84R30KC1 / Tranexamic Acid
  •  go-up   go-down


16. Kanzaki M, Seki Y, Maeda M, Miyoshi S: [A fatal case of meningeal carcinomatosis in a stage IV rectal cancer patient who had long time survival by multi- line chemotherapy]. Gan To Kagaku Ryoho; 2009 Mar;36(3):509-11
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A fatal case of meningeal carcinomatosis in a stage IV rectal cancer patient who had long time survival by multi- line chemotherapy].
  • A 65-year-old man was referred with Stage IV rectal cancer with lung and liver metastasis.
  • One month after operation, he was administered anti-cancer drugs of FOLFOX4 protocol.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Meningeal Carcinomatosis / drug therapy. Neoplasms, Multiple Primary / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295283.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Julien LA, Thorson AG: Current neoadjuvant strategies in rectal cancer. J Surg Oncol; 2010 Mar 15;101(4):321-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current neoadjuvant strategies in rectal cancer.
  • Treatment modalities in rectal cancer have undergone a slow, evolutionary transition over the past 30 years.
  • In this review we focus on current evidence-based neoadjuvant strategies used in the treatment of locally advanced rectal cancer and metastatic rectal disease.
  • [MeSH-major] Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187066.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 32
  •  go-up   go-down


18. Kobayashi K, Kaneko M, Fujiwara M, Otsubo M, Ogura S, Isaka T, Imai N, Naota H, Taniguchi K: [A CR case of colorectal cancer given 39 courses of FOLFOX]. Gan To Kagaku Ryoho; 2009 Jan;36(1):135-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A CR case of colorectal cancer given 39 courses of FOLFOX].
  • We report a CR case of advanced rectal cancer successfully treated with 39 courses of mFOLFOX6.
  • The patient was a 29-year-old female with Stage IV rectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151580.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


19. Meza-Junco J, Wong C, Fields A, Sawyer MB: Esophageal ulcer in a patient who received bevacizumab. Invest New Drugs; 2010 Feb;28(1):98-101
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old woman with metastatic rectal cancer who after surgical resection of the primary and creation of a palliative ileostomy in May 2006, was started on a regimen of bevacizumab, irinotecan, 5-fluouracil and leucovorin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330552.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


20. Soda H, Doi K, Kinoshita T, Yamamoto H, Nagata M, Takiguchi N, Ikeda A, Kainuma O, Cho A, Gunji H, Miyazaki A, Irei S, Itami M: Mandibular bone metastasis of rectal cancer: Report of a case. Surg Today; 2010 Dec;40(12):1188-91
Genetic Alliance. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mandibular bone metastasis of rectal cancer: Report of a case.
  • A 56-year-old man was referred with lower rectal cancer showing anal canal invasion and liver metastasis.
  • The pathological diagnosis was metastatic rectal cancer, and the therapeutic effect chemoradiotherapy was Grade 2.
  • He is presently alive without any evidence of cancer, and has maintained a good quality of life 3 years after the mandibular resection and more than 5 years after his first operation.
  • Mandibular metastasis from rectal cancer is very rare and the prognosis is poor according to the literature, so this case is considered to be very unusual.
  • [MeSH-major] Mandibular Neoplasms / secondary. Mandibular Neoplasms / surgery. Rectal Neoplasms / secondary. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21110168.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Wirsing K, Lorenzo-Rivero S, Luchtefeld M, Kim D, Monroe T, Attal H, Hoedema R: Local excision of stratified T1 rectal cancer. Am J Surg; 2006 Mar;191(3):410-2
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local excision of stratified T1 rectal cancer.
  • BACKGROUND: Local excision has been accepted therapy for T1 rectal cancers.
  • METHODS: This was a 34-year retrospective review of patients who had transrectal excision with clear margins for T1 rectal cancer.
  • RESULTS: Of 101 patients with T1 rectal cancer undergoing local excision, 31 had a full-thickness transrectal excision.
  • Four patients (13%) died from metastatic rectal cancer.
  • CONCLUSIONS: The recurrence rate for transrectal excision of T1 rectal cancer is high.
  • It may be beneficial for patients with early rectal cancer to have postoperative chemoradiation therapy or a more radical surgical procedure.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / surgery. Intestinal Mucosa / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490557.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gensheimer M, Jones CA, Graves CR, Merchant NB, Lockhart AC: Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol; 2009 Jan;63(2):371-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of oxaliplatin to a pregnant woman with rectal cancer.
  • PURPOSE: The platinum agent oxaliplatin could be useful in treatment of cancer in pregnant women, but it is fetotoxic in rats and its effect on the human fetus is unknown.
  • METHODS: Oxaliplatin was administered to a 25-year-old pregnant woman with metastatic rectal cancer from 20 to 30 weeks gestational age as part of the mFOLFOX-6 regimen.
  • [MeSH-major] Fetal Development / drug effects. Liver Neoplasms / drug therapy. Organoplatinum Compounds. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357450.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


23. Sugimoto M, Yasuda H, Koda K, Yamazaki M, Tezuka T, Takenoue T, Kosugi C, Higuchi R, Yamamoto S, Watayo Y, Yagawa Y, Suzuki M: Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. Hepatogastroenterology; 2007 Sep;54(78):1684-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
  • Liver metastasis is an important prognostic factor in colorectal cancer.
  • The efficacy of resection of metastatic lesions in liver metastasis of colorectal cancer is also widely recognized.
  • The current status and new therapeutic significance of FOLFOX therapy are discussed based on the literature of colorectal cancer chemotherapy to date, and the clinical experience in which we obtained CR for liver metastasis is reported.
  • The patient had stage IV rectal cancer, perforative peritonitis, pelvic abscess and simultaneous multiple liver metastasis.
  • FOLFOX was suggested to have new clinical significance in oncologic emergencies against unresectable liver metastasis in colorectal cancer and should serve as adjuvant chemotherapy that will contribute to improvement of treatment results.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019695.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


24. Bragg J, Pomeranz MK: Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab. Dermatol Online J; 2007;13(1):1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients receiving epidermal growth factor receptor inhibitors for cancer treatment developed papulopustular eruptions a few days after starting treatment.
  • One patient is a 56-year-old man with metastatic lung cancer treated with erlotinib.
  • The other patient is a 53-year-old man with metastatic rectal cancer treated with cetuximab.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal, Humanized. Cetuximab. Erlotinib Hydrochloride. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Middle Aged. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Rosacea.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511934.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


25. Patwardhan M, Fisher DA, Mantyh CR, McCrory DC, Morse MA, Prosnitz RG, Cline K, Samsa GP: Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature). J Eval Clin Pract; 2007 Dec;13(6):831-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature).
  • RATIONALE, AIMS AND OBJECTIVES: The burden of illness from colorectal cancer (CRC) can be reduced by improving the quality of care.
  • No measures are available for assessing quality of management of stage IV rectal cancer and hepatic metastasis; chemotherapy for stage II colon cancer; and procedure notes.
  • [MeSH-major] Colonic Neoplasms / therapy. Quality Assurance, Health Care / standards. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070253.001).
  • [ISSN] 1356-1294
  • [Journal-full-title] Journal of evaluation in clinical practice
  • [ISO-abbreviation] J Eval Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 117
  •  go-up   go-down


26. Gazoni LM, Hedrick TL, Smith PW, Friel CM, Swenson BR, Adams JD, Lisle TC, Foley EF, Ledesma EJ: Cutaneous metastases in patients with rectal cancer: a report of six cases. Am Surg; 2008 Feb;74(2):138-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases in patients with rectal cancer: a report of six cases.
  • Cutaneous metastases from rectal cancer are rare manifestations of disseminated disease and uniformly represent dismal survival.
  • A retrospective review of six patients with rectal cancer metastatic to the dermis was performed.
  • The diagnosis of rectal cancer was made concurrently with the diagnosis of the dermal metastases in all six patients.
  • A 100 per cent histopathologic concordance existed between the tissue of the dermal metastases and primary rectal tumor.
  • The progression of systemic metastatic disease was the cause of death in 83.3 per cent of patients (5/6).
  • Recognition of suspicious skin lesions as possible harbingers of undiagnosed visceral malignancy is important in managing patients both with and without a history of previous cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306865.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Fujii S, Ota M, Ichikawa Y, Yamagishi S, Osada S, Suwa H, Kunisaki C, Ohki S, Endo I: Paraaortic lymph node metastasis showed CR to UFT/LV therapy in elderly rectal cancer. Hepatogastroenterology; 2010 May-Jun;57(99-100):472-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraaortic lymph node metastasis showed CR to UFT/LV therapy in elderly rectal cancer.
  • BACKGROUND/AIMS: Intravenous chemotherapy with a combination of several drugs is commonly used to treat metastatic colorectal cancer.
  • Here we report a rare case of metastatic rectal cancer in an elderly patient who got complete response for metastatic rectal cancer with oral uracil-tegafur plus leucovorin therapy.
  • An abdominoperineal resection of the rectum was performed, but para-aortic lymph-node metastasis occurred.
  • CONCLUSIONS: This case demonstrates that uracil-tegafur plus leucovorin therapy can be used safely even in elderly patients, and suggests that it is likely to be effective in treating metastatic colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698211.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


28. Yamagishi Y, Okada Y, Ishikawa M, Mizuno A, Katano K, Fujita M: [A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1959-63
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage].
  • We report a case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa that responded to mFOLFOX6 chemotherapy and enabled survival for 19 months.
  • A colonoscopy and barium enema revealed diffusely infiltrating rectal cancer.
  • Abdominal CT and PET showed lymphangitis carcinomatosa of the lung, paraaortic lymph node swelling, and left hydronephrosis due to rectal cancer.
  • The patient was diagnosed with stage IV rectal cancer.
  • Thus, mFOLFOX6 chemotherapy could be an effective salvage regimen in cases of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lymphangitis / drug therapy. Lymphangitis / etiology. Rectal Neoplasms / complications. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011352.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


29. Zhang JD, Dai Y, Yu JM, Shao ZY: [Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer]. Zhonghua Yi Xue Za Zhi; 2010 Apr 13;90(14):982-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
  • OBJECTIVE: To evaluate the efficacy of accelerated hyperfractionation (CAF) radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer.
  • METHODS: Between June 2004 and January 2008, 53 patients with locoregional recurrent rectal cancer were treated with CAF 1.2 Gy/f, 2 f/d plus concurrent capecitabine at an oral dosage of 825 mg/m2 bid on each day of radiotherapy period.
  • CONCLUSION: The 3-dimensional conformal radiotherapy plus concurrent chemotherapy may be an effective and well-tolerated regimen in patients with postoperative locoregional recurrent or metastatic rectal cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646649.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. O'Neil BH, Tepper JE: Current options for the management of rectal cancer. Curr Treat Options Oncol; 2007 Oct;8(5):331-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current options for the management of rectal cancer.
  • Patients diagnosed with rectal cancer should undergo locoregional staging with transrectal endoscopic ultrasound (EUS) or surface coil array MRI of the pelvis if that technique is available.
  • Patients thought to have more than very early stage (T1 or T2) disease should undergo abdominal imaging as well by CT or MRI, and chest imaging with either CXR or preferably CT.
  • The care of rectal cancer patients should be coordinated amongst an experienced multidisciplinary team to maximize the chance of cure and to minimize both local recurrence and complications of therapy.
  • For patients with very early stage disease (T1N0 or T2N0), local resection with or without chemoradiation may be adequate therapy, but these patients must be selected carefully and should be without any poor prognostic factors.
  • For the majority of patients with T3N0 or greater rectal cancer, standard therapy consists of neoadjuvant continuous 5-FU and radiation followed by surgery and further chemotherapy (either with 5-FU, capecitabine, or FOLFOX).
  • Patients with stage IV rectal cancer may still require local therapy with radiation, surgery, or both; however, care should be taken in these patients that chemotherapy is not excessively delayed as this is the one modality in this case that can result in improved survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181024.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K23 CA 118431-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 51
  •  go-up   go-down


31. Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W Jr, Zook J, Konski AA: ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer; 2010 May-Jun;34(3):201-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation.
  • In 2009, an estimated 40,870 new cases of rectal cancer will be diagnosed in the USA.
  • After decades of treating metastatic colorectal cancer (CRC) with 5-fluorouracil alone, newer agents have resulted in significant improvements in disease-free and overall survival rates.
  • Based on performance status and burden of disease, metastatic CRC patients are generally treated with either a curative or palliative intent.
  • In select patients with metastatic CRC, neoadjuvant or adjuvant pelvic chemoradiation (CRT) is indicated to prevent local recurrence.
  • Patients who have resectable metastatic disease with symptomatic, obstructive, Stage T3-4 and N1, or low-lying (<or=5 cm) primary tumors should be considered for neoadjuvant CRT.
  • This review summarizes the current literature on metastatic CRC and presents 4 simulated patient variants.
  • [MeSH-major] Guideline Adherence. Liver Neoplasms / therapy. Practice Guidelines as Topic. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Radiology. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20541058.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


32. Guo W, Tang S, Yang RL, Ji T: [Total elbow arthroplasty after resection of tumors at the elbow]. Zhonghua Wai Ke Za Zhi; 2008 Nov 15;46(22):1734-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between June 1998 to June 2007, 19 patients underwent total elbow arthroplasty after resection of tumors at the authors department, which involved 13 males and 6 females, including 6 patients with metastatic tumor, 1 with giant cell tumor of bone (GCT), 2 with malignant fibrous histiocytoma (MFH), 4 with osteosarcoma, 3 with Ewing sarcoma, l with lymphoma, 1 with synovial sarcoma, and 1 with desmoid fibroma of the bone.
  • During the following up time, 2 patients with metastatic lung cancer, 1 with metastatic rectal cancer and 1 with ovarian cancer died in 2 years after surgery.
  • For metastatic tumors, this technique also can be used if there is no other good option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094737.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Sato Y, Takayama T, Nikaido T, Wada Y, Sagawa T, Abe S, Sato T, Iyama S, Murase K, Araki H, Sato Y, Kato J, Niitsu Y, Chiba H: Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis. Nihon Shokakibyo Gakkai Zasshi; 2007 Sep;104(9):1365-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
  • However, it is still under discussion whether ALS occurring in cancer patients is paraneoplastic.
  • A 60-year-old man with rectal cancer (Stage IV) having multiple lung, liver and para-aortic lymph node metastases underwent anterior resection of the rectum as palliative surgery.
  • As a result, the size the of metastatic lesions markedly reduced and CEA was decreased to the normal level.
  • Autopsy revealed that his neuropathological findings were compatible with ALS, and it was thought to be the primary cause of death in the because of absence of cancer progression.
  • In this case the neurological syndrome was not affected by cancer therapy.
  • Thus our case does not support the hypothesis that ALS in associated with cancer and the relationship between both disorders remains uncertain.

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827908.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


34. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Toppan P, Rugge M, Sinigaglia G, Nitti D, Sotti G, Monfardini S: Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Anticancer Res; 2007 Mar-Apr;27(2):1079-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
  • BACKGROUND: Rectal cancer is commonly diagnosed at a precocious stage, but for patients presenting at diagnosis with stage IV disease the best treatment is still undefined.
  • The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 40 patients with histologically proven stage IV rectal adenocarcinoma (< 12 cm from the anal verge) were examined.
  • Seventeen patients with unresectable or potentially resectable metastatic disease received neoadjuvant chemoradiotherapy (CHT-RT) with 5-fluorouracil (5FU) (plus oxaliplatin in 11 cases), radical surgery was performed in almost half of the cases; only in two patients were metastases also resected.
  • If the patient is a candidate for radical surgical resection, the primary tumour should initially be treated as in a patient without metastatic disease and subsequently the primary tumour and metastases should be treated surgically.
  • CONCLUSION: The best treatment on diagnosis of metastatic rectal cancer is a multimodality CHT-RT approach.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


35. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P: Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res; 2005 Jul 1;11(13):4754-60
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
  • PURPOSE: Cyclooxygenase-2 (COX-2) expression in human colorectal cancer and adenoma tissue seems to be higher than in normal mucosa.
  • Therefore, we studied COX-2 expression in surgery tissue and survival time in a cohort of 747 colorectal cancer patients.
  • EXPERIMENTAL DESIGN: Surgical specimens of primary colorectal cancer from 747 individuals were immunostained for COX-2 and evaluated under a transmission light microscope.
  • Similar results were obtained when stage IV and rectal cancer patients were excluded from the analysis.
  • CONCLUSIONS: COX-2 expression in tumor epithelial cells does not seem to be related to survival of colorectal cancer patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000571.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Osarogiagbon RU, Ogbeide O, Ogbeide E, George RK: Hand-assisted laparoscopic colectomy compared with open colectomy in a nontertiary care setting. Clin Colorectal Cancer; 2007 Jul;6(8):588-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this retrospective case review of consecutive patients undergoing HALC for colon tumors from April 2003 to September 2004 compared with patients who had open colectomy, patients with rectal cancer and stage IV disease were excluded, and reported variables were compared by the nonparametric Mann-Whitney U test; all P values are 2-tailed.
  • Stage distribution was as follows: stage 0, 23% versus 11%; stage I, 23% versus 23%; stage II, 31% versus 36%; and stage III, 23% versus 31%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681106.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Coevoet H, Woelffle D, Quinton JF, Hector E, Bonnière X, Boruchowicz A: [Distal pancreatectomy for rectal metastatic adenocarcinoma 6 years after proctectomy]. Gastroenterol Clin Biol; 2007 Jun-Jul;31(6-7):624-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distal pancreatectomy for rectal metastatic adenocarcinoma 6 years after proctectomy].
  • [Transliterated title] Pancréatectomie caudale pour métastase d'un adénocarcinome rectal 6 ans après exérèse de la tumeur primitive.
  • We report the case of a 77 year old man treated with a distal pancreatectomy for rectal metastatic cancer.
  • Diagnosis was made based on increased CEA levels following excision of the rectal tumor discovered during treatment follow up of liver and pulmonary metastases.
  • Pancreatic resection for metastatic colonic adenocarcinoma of the pancreas may be considered in selected patients without extrapancreatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646794.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Shitara K, Munakata M, Muto O, Sakata Y: Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report. Jpn J Clin Oncol; 2008 Jul;38(7):493-6
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report.
  • A 61-year-old female with surgically treated rectal cancer that had metastasized to lung and lymph nodes was treated with bevacizumab (BV) plus 5-fluorouracil (5-FU) and leucovorin (LV) as third-line chemotherapy after treatment failures with infusional 5-FU, LV and oxaliplatin (FOLFOX regimen); and infusional 5-FU, LV and irinotecan (FOLFIRI regimen).
  • Although there are no clinical trial results supporting the use of BV-containing therapy as third-line chemotherapy for advanced colorectal cancer, BV plus 5-FU and LV was effective and feasible in our patient with colon cancer that had progressed after treatment with 5-FU, irinotecan and oxaliplatin.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Rectal Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567598.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


39. Nieuwenhuis MH, Hartgrink HH, Meijer S, Menko FH, Vasen HF: [Desmoid tumour as indication of familial adenomatous polyposis]. Ned Tijdschr Geneeskd; 2010;154:A2235
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second patient had developed metastatic rectal cancer.
  • [MeSH-minor] Adult. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Female. Genes, APC. Genetic Predisposition to Disease. Humans. Male. Mutation. Neoplasm Metastasis. Rectal Neoplasms / diagnosis. Rectal Neoplasms / secondary. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20977806.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Romano G, Bianco F, Delrio P, Cremona F, Ruffolo F, Pace U, Sassaroli C, Scala D, De Franciscis S, Cardone E, Atelli PF: From mininvasive to maxinvasive surgery in colorectal cancer: modem evolution of oncologic specialized units. Acta Chir Iugosl; 2010;57(3):73-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From mininvasive to maxinvasive surgery in colorectal cancer: modem evolution of oncologic specialized units.
  • In the last years a wide range of new technique offers the possibility to have R0 resection in colorectal cancer.
  • We report our experience about Single Port Laparoscopic Surgery (SPL) for not advanced right colon cancer and about pelvectomy with cilindric Abdominal Perineal Resection (APR) for advanced rectal cancer.
  • With advanced pelvic cancer, pelvic exenteration with en-bloc resection is indicated.
  • Then we propose a case of a 55 years old woman with a pelvic recurrence from a metastatic rectal cancer involving the right obturator fossa, the vaginal stump, the right ureter.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066988.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


41. Celiku E, Draçini X, Dibra A, Di Matteo FM, Catania A: Rectal cancer surgery. A ten years experience. G Chir; 2010 Nov-Dec;31(11-12):507-10
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer surgery. A ten years experience.
  • Rectal cancer is one of the most common malignancies in the western world population.
  • The management of rectal cancer has changed thoroughly in recent years owing to the rapid advances in surgical techniques, imaging and adjuvant therapy.
  • The present study analyses extensively 152 patients operated for diagnosis of, rectal cancer in the First Clinic of General Surgery UHC "Mother Theresa" in Tirana, Albania, in a ten years period.
  • 30% of all patients resulted stage D, according to the Astler - Coller classification.
  • The surgical treatment of rectal cancer has changed radically in recent years in Albania.
  • [MeSH-major] Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21232193.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol; 2006 Oct;63(10):1475-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
  • PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma / drug therapy. Colonic Neoplasms / drug therapy. Dementia, Vascular / chemically induced. Liver Neoplasms / drug therapy. Occipital Lobe / drug effects

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030665.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


43. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, Nishizaki D, Iwasa Y: The role of prophylactic bilateral oophorectomy at the time of initial diagnosis of a unilateral ovarian metastasis in cases with colorectal adenocarcinoma. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):434-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Case 1 is a 63-year-old with ascending colon carcinoma, Dukes' C, and right oophorectomy due to metachronous ovarian metastasis.
  • Case 2 is a 28-year-old with transverse colon carcinoma, Dukes' D, and right oophorectomy due to synchronous ovarian metastasis.
  • Case 3 is a 40-year-old with rectal carcinoma, Dukes' B, and right oophorectomy due to metachronous ovarian metastasis.
  • Case 4 is a 32-year-old with rectal carcinoma, Dukes' D, and bilateral oophorectomy due to synchronous and metachronous ovarian metastases.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613382.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


44. Dakubo JC, Naaeder SB, Tettey Y, Gyasi RK: Colorectal carcinoma: an update of current trends in Accra. West Afr J Med; 2010 May-Jun;29(3):178-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: an update of current trends in Accra.
  • BACKGROUND: Clinical experience and earlier studies indicate that the number of colorectal cancer cases seen annually in the Accra metropolis is increasing.
  • OBJECTIVE: This study was aimed at providing a current update on colorectal cancer in Accra, Ghana.
  • METHODS: A prospective study of confirmed cases of colorectal cancer diagnosed from January 1997- December 2007.
  • RESULTS: Three hundred and fifty-nine colorectal cancer cases were studied.
  • Rectal bleeding 185(51.1%), abdominal mass 76(21.1%), intestinal obstruction 62(17.3%), intestinal perforation nine (2.5%) and iron deficiency anaemia nine (2.5%) cases were the main presentations.
  • There were 168 (46.8%) rectal and 191(53.2%) colon tumours.
  • The Astler Coller stages of the tumours at diagnosis were C2 84(36.7%), C1 53(22.1%), B2 49(21.4%), D 17(7.4%), B1 14(6.1%) and A 12(5.1%) cases.
  • CONCLUSION: The incidence of colorectal cancer has increased over the last four decades in tandem with an aging population of Accra with adenocarcinoma as the predominant histological type.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20665462.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down






Advertisement